Evogliptin: First Global Approval

Drugs

Volumn 75, Issue 17, 2015, Pages 2045-2049

  McCormack, Paul L ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EVOGLIPTIN; HEMOGLOBIN A1C; 4-(3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL)-3-(TERT-BUTOXYMETHYL)PIPERAZIN-2-ONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PIPERAZINE DERIVATIVE;

ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD GLUCOSE MONITORING; CHEMICAL STRUCTURE; DIABETIC PATIENT; DRUG APPROVAL; HUMAN; IC50; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SOUTH KOREA; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG APPROVAL; HUMANS; PIPERAZINES;

EID: 84946907635     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0496-5     Document Type: Article

References (17)

1. International Diabetes Federation. Global guideline for type 2 diabetes. 2012. http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf. Accessed 12 Oct 2015.
2. Ministry of Food and Drug Safety. MFDS approval of a new, domestically-developed, oral antihyperglycaemic agent [in Korean] [media release]. 2 Oct 2015. http://www.mfds.go.kr/index.do?mid=675&pageNo=1&seq=28999&cmd=v.
3. PipelineReview.com. Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea. 2015. http://www.pipelinereview.com/index.php/2015100259148/Small-Molecules/Dong-A-STs-DPP4-inhibitor-SUGANON-got-approved-for-type-2-diabetes-in-Korea.html. Accessed 13 Oct 2015.
4. Dong-A ST. 2Q 2015 Performance Results. 2015. http://en.donga-st.com/B05.da?method=IRResourceList. Accessed 13 Oct 2015.
5. Dong-A ST. 2014 Annual report. 2015. http://en.donga-st.com/Pass.da?viewPath=/b05/IRReport. Accessed 13 Oct 2015.
6. Dong-A ST. 1Q 2015 Performance results. 2015. http://en.donga-st.com/B05.da?method=IRResourceList. Accessed 13 Oct 2015.
7. Luye Pharma Group, Dong A. Pharma Co Ltd. Luye Pharma obtains the exclusive license of new antidiabetic preparation in China from Dong-A Phama Co., Ltd. - DPP-IV inhibitor DA-1229 [media release]. 17 Feb 2012.
8. Kim HJ, Kwak WY, Min JP, et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011;21(12):3809-12.
9. Chen XW, He ZX, Zhou ZW, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42(10):999-1024.
10. Kim M-K, Chae YN, Kim HD, et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012;90(1):21-9.
11. Gu N, Park MK, Kim TE, et al. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther. 2014;8:1709-21.
12. Cho JM, Jang HW, Cheon H, et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis. Diabetes Res Clin Pract. 2011;91(1):72-9.
13. Kim TE, Lim KS, Park MK, et al. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. Clin Ther. 2012;34(9):1986-98.
14. Park KJ, Shim HJ. Metabolism and excretion of [14C]evogliptin, a DPP-4 inhibitor, in rats [abstract no. P323]. Drug Metab Rev. 2014;45(Suppl 1):195.
15. Won JC. The new DPP-IV inhibitor: evogliptin. Results of clinical trials. In: 2015 International Congress on obesity and metabolic syndrome - satellite symposium 3. http://www.icomes.or.kr/program/sub02-11.html. Accessed 30 Oct 2015.
16. Jung CH, Park CY, Ahn KJ, et al. A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes Metab Res Rev. 2015;31(3):295-306.
17. Dong-A ST. 4Q 2014 performance results. 2015. http://en.donga-st.com/B05.da?method=IRResourceList. Accessed 20 Oct 2015.